IL6 and rheumatoid arthritis: Analysis of data from 353 patients with D2T RA in the FIRST registry in Japan showed that JAKis significantly improved CDAI compared to TNFis after adjustment using the propensity-based inverse probability treatment weighted method whereas for IL-6 inhibitors and abatacept, CDAI improvement was not significantly different from that of TNFi.